Researchers have identified a molecular signal in blood that could help detect early precancerous changes associated with ovarian cancer, potentially opening a new direction for identifying the disease before invasive cancer develops. The study, published in Nature Medicine, examined an RNA molecule called Tu-Stroma, which was found at elevated levels in women with a condition known as serous tubal intraepithelial carcinoma (STIC). STIC involves abnormal cellular changes in the lining of the fallopian tubes and is recognised as a precursor to some forms of ovarian cancer. Researchers have increasingly focused on identifying these changes because ovarian cancer is often diagnosed after it has already spread. The research team reported that measuring Tu-Stroma in blood detected STIC in 92.3% of affected women. The test also correctly identified 98.2% of healthy women in the study. Among women with inherited genetic risk factors for ovarian cancer, approximately 72% of positive results were accurate, while negative results were correct nearly 100% of the time, according to the researchers. Study leader Rajan Gogna of the Hoag Family Cancer Institute in California said the research takes a different approach to early detection by looking for molecular warning signs before invasive cancer develops. Co-author Dr Esha Madan said the findings could eventually help inform prevention decisions for women at high risk, including those considering preventive surgery involving the fallopian tubes and ovaries. However, the findings represent an early research development, not an established screening test. Further independent validation and clinical studies will be necessary before its use in routine medical practice can be determined.
Blood Test Shows Promise for Early Detection of Ovarian Cancer
Researchers have identified a blood-based molecular signal called Tu-Stroma that could help detect precancerous changes associated with ovarian cancer. Published in Nature Medicine, the study reports promising detection results, potentially offering new insights for women at increased genetic risk.


0 comments
No comments yet. Yours would be the first.